Potential breakthroughs with investigational drugs for hairy cell leukemia

Bibliography

• Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 1958;13:609–30
   PubMed Web of Science ®Google Scholar
• Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia: an update. Curr Opin Hematol 2003;10:258–66
   PubMed Web of Science ®Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374–403
   PubMed Web of Science ®Google Scholar
• Foucar K, Falini B, Catovsky D, Stein H. WHO classification of tumours of haemtopoietic and lymphoid tissues. In: Swerdlow SH, Harris NL, Jaffe ES, et al. editors. Hairy cell lymphoma. IARC; Lyon: 2008. p. 188–90
   Google Scholar
• Matutes E. Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol Oncol Clin North Am 2006;20:1051–63
   PubMed Web of Science ®Google Scholar
• Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004;363:1869–70
   PubMed Web of Science ®Google Scholar
• Robak T. Hairy cell leukemia variant: Recent view on diagnosis, biology and treatment. Cancer Treat Rev 2011;37:3–10
   PubMed Web of Science ®Google Scholar
• Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy cell leukemia. N Engl J Med 2011;364:2305–15
   PubMed Web of Science ®Google Scholar
• Robak T, Robak P. Purine nucleoside e analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des 2012;18:3373–88
   PubMed Web of Science ®Google Scholar
• Robak T, Matutes E, Catovsky D, et al. Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; pii: mdv200. [Epub ahead of print]
   Google Scholar
• Tiacci E, Liso A, Piris M, Falini B. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat Rev Cancer 2006;6:437–48
   PubMed Web of Science ®Google Scholar
• Forconi F, Cencini E, Sicuranza A, et al. Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis. Leuk Lymphoma 2011;52:15–23
   PubMed Web of Science ®Google Scholar
• Hockley SL, Else M, Morilla A, et al. The prognostic impact of clinical and molecular features in hairy cell leukaemia-variant and splenic marginal zone lymphoma. Br J Haematol 2012;158:347–54
   PubMed Web of Science ®Google Scholar
• Forconi F, Sozzi E, Cencini E. Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behaviour. Blood 2009;141:4696–702
   Web of Science ®Google Scholar
• Arons E, Kreitman RJ. Molecular variant of hairy cell leukemia with poor prognosis. Leuk Lymphoma 2011;52(Suppl 2):99–102
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949–54
   PubMed Web of Science ®Google Scholar
• Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 2012;119:3330–2
   PubMed Web of Science ®Google Scholar
• Park JH, Levine RL. Targeted immunotherapy for hairy cell leukemia. J Clin Oncol 2012;30:1888–90
   PubMed Web of Science ®Google Scholar
• Tiacci E, Schiavoni G, Forconi F, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 2012;119:192–5
   PubMed Web of Science ®Google Scholar
• Arcaini L, Zibellini S, Boveri E, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 2012;119:188–91
   PubMed Web of Science ®Google Scholar
• Jain P, Ok CY, Konoplev S, et al. Relapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemia: a distinct entity? J Clin Oncol 2014. [Epub ahead of print]
   Google Scholar
• Kreitman RJ. Hairy cell leukemia-new genes, new targets. Curr Hematol Malig Rep 2013;8:184–95
   PubMed Web of Science ®Google Scholar
• Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 2012;119:3330–2
   PubMed Web of Science ®Google Scholar
• Waterfall JJ, Arons E, Walker RL, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet 2014;46:8–10
   PubMed Web of Science ®Google Scholar
• Pettirossi V, Santi A, Imperi E, et al. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood 2015;125:1207–16
   PubMed Web of Science ®Google Scholar
• Dietrich S, Hüllein J, Lee SC, et al. Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood 2015; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Robak T, Smolewski P. New mutation in hairy cell leukemia. Blood 2015; In press
   Google Scholar
• Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008;8:253–67
   PubMed Web of Science ®Google Scholar
• Shin S-Y, Seung-Tae Lee S-T, Kim H-J, et al. BRAF V600E and MAP2K1 mutations in hairy cell leukemia and splenic marginal zone lymphoma cases. Ann Lab Med 2015;35:257–9
   Google Scholar
• Noel P. Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunohistology specimens. Leuk Lymphoma 2011;52(Suppl 2):62–4
   PubMedGoogle Scholar
• Garnache Ottou F, Chandesris MO, Lhermitte L, et al. Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high-risk patients. Br J Haematol 2014;166:50–9
   PubMed Web of Science ®Google Scholar
• Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010;115:1893–6
   PubMed Web of Science ®Google Scholar
• Jain P, Polliack A, Ravandi F. Novel therapeutic options for relapsed hairy cell leukemia. Leuk Lymphoma 2015; [Epub ahead of print]
   Google Scholar
• Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009;114:4687–95
   PubMed Web of Science ®Google Scholar
• Spiers AS, Parekh S.L, Bishop MB. Hairy cell leukaemia: induction of complete remission with pentostatin (2’-deoxycoformycin). J Clin Oncol 1984;2:1336–42
   PubMed Web of Science ®Google Scholar
• Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy cell leucemia induced by a single infusión of 2-chlorodeoxyadenosine. N Engl J Med 1990;322:1117–21
   PubMed Web of Science ®Google Scholar
• Cheson BD, Sorensen JM, Vena DA. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group Protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:3007–15
   PubMed Web of Science ®Google Scholar
• Robak T, Blasinska-Morawiec M, Krykowski E, et al. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma 1996;22:107–11
   PubMed Web of Science ®Google Scholar
• Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia treated initially with pentostatin or cladribine at a median of 16 years. Br J Haematol 2009;145:733–40
   PubMed Web of Science ®Google Scholar
• Dearden CE, Else M, Catovsky D. Long term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma 2011;52(Suppl 2):21–4
   PubMed Web of Science ®Google Scholar
• Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010;115:1893–6
   PubMed Web of Science ®Google Scholar
• Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007;109:3672–5
   PubMed Web of Science ®Google Scholar
• Cornet E, Delmer A, Feugier P, et al. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia. Ann Hematol 2014;93:1977–83
   PubMed Web of Science ®Google Scholar
• Jones G, Parry-Jones N, Wilkins B, et al. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol 2012;156:186–95
   PubMed Web of Science ®Google Scholar
• Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 2006;32:365–76
   PubMed Web of Science ®Google Scholar
• Seymour JF, Estey EH, Keating MJ, Kurzrock R. Response to interferon- in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia 1995;9:929–32
   PubMed Web of Science ®Google Scholar
• Hoffman MA. Interferon-alpha is a very effective salvage therapy for patients with hairy cell leukemia relapsing after cladribine: a report of three cases. Med Oncol 2011;28:1537–41
   PubMed Web of Science ®Google Scholar
• Quesada JR, Reuben J, Manning JT, et al. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984;310:15–18
   PubMed Web of Science ®Google Scholar
• Habermann TM, Andersen JW, Cassileth PA, et al. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br J Haematol 1992;80:466–71
   PubMed Web of Science ®Google Scholar
• Habermann TM, Rai K. Historical treatments of in hairy cell leukemia, splenectomy and interferon: past and current uses. Leuk Lymphoma 2011;52:18–20
   PubMed Web of Science ®Google Scholar
• Robak T. Rituximab for chronic lymphocytic leukemia. Expert Opin Biol Ther 2012;12:503–15
   PubMed Web of Science ®Google Scholar
• Hagberg H, Lundholm L. Rituximab, a chimeric anti-CD20 monoclonal antibody in the treatment of hairy cell leukaemia. Br J Haematol 2001;115:609–11
   PubMed Web of Science ®Google Scholar
• Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102:810–13
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Bueso-Ramos C. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102:3906–11
   PubMed Web of Science ®Google Scholar
• Leclerc M, Suarez F, Noel MP, et al. Rituximab therapy for hairy cell leukemia:A retrospective study of 41 cases. Ann Hematol 2015;94:89–95
   PubMed Web of Science ®Google Scholar
• Akinosoglou K, Melachrinou M, Makatsoris T, et al. Rituximab as frontline monotherapy in untreated hairy cell leukemia patients. Ann Hematol 2015;94:1069–70
   PubMed Web of Science ®Google Scholar
• Malfuson JV, Fagot T, Konopacki J, et al. Which role for rituximab in hairy cell leukemia? Reflections on six cases. Acta Haematol 2010;123:110–16
   PubMed Web of Science ®Google Scholar
• Angelopoulou MK, Pangalis GA, Sachanas S, et al. Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab. Leuk Lymphoma 2008;49:1817–20
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien S, Jorgensen J, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 2011;118:3818–23
   PubMed Web of Science ®Google Scholar
• Ravandi F. Chemo-immunotherapy for hairy cell leukemia. Leuk lymphoma 2011;52(Suppl 2):72–4
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson W, Calvo KR, et al. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res 2013;19:6873–81
   PubMed Web of Science ®Google Scholar
• Else M, Dearden CE, Matutes E, et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma 2011;52:75–8
   PubMed Web of Science ®Google Scholar
• Leclerc M, Suarez F, Noel MP, et al. Rituximab therapy for hairy cell leukemia:A retrospective study of 41 cases. Ann Hematol 2015;94:89–95
   PubMed Web of Science ®Google Scholar
• Gerrie AS, Zypchen LN, Connors JM. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood 2012;119:1988–91
   PubMed Web of Science ®Google Scholar
• Burotto M, Stetler-Stevenson M, Arons E, et al. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res 2013;19:6313–21
   PubMed Web of Science ®Google Scholar
• Robak T, Robak E. Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 2014;23:911–24
   PubMed Web of Science ®Google Scholar
• Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 2009;9:1445–51
   PubMed Web of Science ®Google Scholar
• Robbins DH, Margulies I, Stetler-Stevenson M, Kreitman RJ. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2). Clin Cancer Res 2000;6:693–700
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18:1622–36
   PubMed Web of Science ®Google Scholar
• Pezzutto A, Rabinovitch PS, Dorken B, et al. Role of the CD22 human B cell antigen in B cell triggering by anti-immunoglobulin. J Immunol 1988;140:1791–5
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009;27:2983–90
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011;17:6398–405
   PubMed Web of Science ®Google Scholar
• Park JH, Levine RL. Targeted immunotherapy for hairy cell leukemia. J Clin Oncol 2012;30:1888–90
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012;30:1822–8
   PubMed Web of Science ®Google Scholar
• Chung SS, Kim E, Park JH, et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med 2014;6:238ra71
   PubMed Web of Science ®Google Scholar
• Tiacci E, Schiavoni G, Martelli MP, et al. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica 2013;98:635–9
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–16
   PubMed Web of Science ®Google Scholar
• Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012;366:2038–40
   PubMed Web of Science ®Google Scholar
• Dietrich S, Hüllein J, Hundemer M, et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol 2013;31:e300–3
   PubMed Web of Science ®Google Scholar
• Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol 2013;31(20):e351–2
   PubMed Web of Science ®Google Scholar
• Peyrade F, Re D, Ginet C, et al. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica 2013;98:e20–2
   PubMed Web of Science ®Google Scholar
• Follows GA, Sims H, Bloxham DM, et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol 2013;161:150–3
   PubMed Web of Science ®Google Scholar
• Park JH, Chung SS, Chung YR, et al. Vemurafenib has potent antitumor activity in patients with relapsed/refractory BRAF mutant hairy cell leukemia. Blood ASH Annual Meeting Abstracts 2014;124:Abstract 24
   Web of Science ®Google Scholar
• Tiacci E, De Carolis L, Zinzani P, et al. Efficacy and safety of the BRAF inhibitor vemurafenib in hairy cell leukemia patients refractory to or relapsed after purine analogs: a phase-2 Italian clinical trial. Blood (ASH Annual Meeting Abstracts) 2014;124:Abstract 150
   Google Scholar
• Dietrich S, Pircher A, Andruli M, et al. BRAF inhibition in hairy cell leukemia: multicentre experience of 21 patients treated with vemurafenib. Blood ASH Annual Meeting Abstracts 2014;124:Abstract 3634
   Web of Science ®Google Scholar
• Bailleux C, Robert G, Ginet C, et al. Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib. Oncoscience 2014;2:44–9
   Google Scholar
• Samuel J, Macip S, Dyer MJ. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med 2014;370:286–8
   PubMed Web of Science ®Google Scholar
• Watts JM, Kishtagari A, Hsu M, et al. Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a surveillance, epidemiology and end results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center. Br J Haematol 2015; Epub ahead of print
   PubMedGoogle Scholar
• Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;37:1867–76
   Web of Science ®Google Scholar
• Vergote V, Dierickx D, Janssens A, et al. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib. Ann Hematol 2014;93:2087–9
   PubMed Web of Science ®Google Scholar
• Hall RD, Kudchadkar RR. BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. Cancer Contr 2014;21:221–30
   PubMed Web of Science ®Google Scholar
• Blachly JS, Lozanski G, Lucas DM, et al. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor. J Natl Compr Canc Netw 2015;13:9–13
   PubMed Web of Science ®Google Scholar
• Vergote V, Dierickx D, Janssens A, et al. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib. Ann Hematol 2014;93:2087–9
   PubMed Web of Science ®Google Scholar
• Robak T, Robak P. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. Int Rev Immunol 2013;32:358–76
   PubMed Web of Science ®Google Scholar
• Sivina M, Kreitman RJ, Arons E, et al. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol 2014;166:177–88
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213–23
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507–16
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med 2015;372:1430–40
   PubMed Web of Science ®Google Scholar
• Jones A, Andritsos L, Ravandi F, et al. Safety and efficacy of the Bruton tyrosine kinase inhibitor ibrutinib in patients with hairy cell leukemia: interim results of a phase 2 study. Haematologica 2015;Abstract: S790
   Google Scholar
• Chandran R, Gardiner SK, Smith SD, Spurgeon SE. Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. Br J Haematol 2013;163:407–9
   PubMed Web of Science ®Google Scholar
• Grever MR. How I treat hairy cell leukemia. Blood 2010;115:21–8
   PubMed Web of Science ®Google Scholar
• Poret N, Fu Q, Guihard S, et al. CD38 in hairy cell leukemia is a marker of poor prognosis and a new target for therapy. Cancer Res 2015; pii: canres.0893.2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Guest JF, Smith H, Sladkevicius E, Jackson G. Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom. Clin Ther 2009;31(Pt 2):2398–415
   PubMed Web of Science ®Google Scholar
• Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed 2013 Oct 25. (n.d.)
   Google Scholar